News

WE LIKE TO KEEP YOU UPDATED

NEWS

Pharmaceutical reshoring: a healthy requirement, a strategic necessity - a Manufacturing Chemist Featured Story

General / 16. April 2021

Pharmaceutical reshoring: a healthy requirement, a strategic necessity - a Manufacturing Chemist Featured Story

Andrew Badrot, CEO of C2 PHARMA, discusses the ongoing ramifications of the pandemic

Read more
C<sup>2</sup> PHARMA Completes Multiple Regulatory Filings, Expands API Portfolio

Press Release / 23. February 2021

C2 PHARMA Completes Multiple Regulatory Filings, Expands API Portfolio

C2 PHARMA solidifies its position as a leading ophthalmic API supplier to the pharmaceutical industry

Read more
Andrew Badrot, C<sup>2</sup> PHARMA CEO, speaks on working to mitigate risks for future crises like the COVID-19 pandemic

General / 18. December 2020

Andrew Badrot, C2 PHARMA CEO, speaks on working to mitigate risks for future crises like the COVID-19 pandemic

C2 PHARMA in Pharma’s Almanac Featured Story

Read more
Interview with Andrew Badrot, C<sup>2</sup> PHARMA CEO

General / 19. November 2020

Interview with Andrew Badrot, C2 PHARMA CEO

A Lëtzebuerger Merkur Featured Story

Read more
C<sup>2</sup> PHARMA Finalist in Excellence in Pharma: Sustainability, the CPhI Pharma Awards 2020

General / 23. September 2020

C2 PHARMA Finalist in Excellence in Pharma: Sustainability, the CPhI Pharma Awards 2020

C2 PHARMA has been shortlisted in the CPhI Awards 2020 for being a key sponsor of the “Partnerships for a Better World” program.

Read more
The Impact of Covid-19 on the Pharmaceutical Industry, a Chemanager Featured Story

General / 31. August 2020

The Impact of Covid-19 on the Pharmaceutical Industry, a Chemanager Featured Story

Andrew Badrot, CEO of C2 Pharma and a close observer of pharma industry trends, analyzes the current situation and how this pandemic may kick of changes in the pharma market.

Read more
Connecting industry across the globe, a Chemicals Knowledge featured story

General / 27. August 2020

Connecting industry across the globe, a Chemicals Knowledge featured story

Andrew Badrot, CEO at C2 PHARMA recently stated that the pharmaceutical industry has responded extremely well to the coronavirus pandemic but that there will be no more ‘business as usual’ in pharmaceutical manufacturing after COVID-19.

Read more
Andrew Badrot, CEO of C<sup>2</sup> PHARMA, speaks on how the pharma industry has responded to the COVID-19 pandemic

General / 1. July 2020

Andrew Badrot, CEO of C2 PHARMA, speaks on how the pharma industry has responded to the COVID-19 pandemic

C2 PHARMA in Pharma’s Almanac Q2 issue

Read more
Lessons from a modern-day pandemic: redesigning the pharmaceutical supply chain, a Manufacturing Chemist featured story

General / 15. May 2020

Lessons from a modern-day pandemic: redesigning the pharmaceutical supply chain, a Manufacturing Chemist featured story

The pharmaceutical industry has responded extremely well to the coronavirus pandemic. At the same time, the industry is changing before our eyes. To put it in simple terms, there will be no more “business-as-usual” in pharmaceutical manufacturing after COVID-19, explains Andrew Badrot, CEO, C2 PHARMA.

Read more
COVID-19/Coronavirus is reshaping the pharmaceutical supply chain, a Chemical & Engineering News Featured Story

General / 27. April 2020

COVID-19/Coronavirus is reshaping the pharmaceutical supply chain, a Chemical & Engineering News Featured Story

The COVID-19/Coronavirus pandemic may mark a rebalancing of where drugs are made as nations recognize a security imperative.

Read more
C<sup>2</sup> PHARMA Opens Government and Research Access to Safety Stock of DIGOXIN API for Use in Potential COVID-19/Coronavirus Combination Treatment

General / 26. March 2020

C2 PHARMA Opens Government and Research Access to Safety Stock of DIGOXIN API for Use in Potential COVID-19/Coronavirus Combination Treatment

LUXEMBOURG, March 26, 2020 /PRNewswire/ — C2 PHARMA (C2P), a Luxembourg-based phytochemical and chemical pharmaceutical manufacturing and distribution group, is announcing that they will open access to safety stocks of the active pharmaceutical ingredient (API), Digoxin. In early March, the API was listed for its potential to reduce the symptoms of COVID-19/Coronavirus patients in combination with other anti-viral drugs based on initial research in South Korea and India.

Read more
Andrew Badrot, CEO of C<sup>2</sup> PHARMA, weighs in on the future trends of mergers and acquisitions in the life sciences industry, a Pharma's Almanac Q1 issue

General / 19. March 2020

Andrew Badrot, CEO of C2 PHARMA, weighs in on the future trends of mergers and acquisitions in the life sciences industry, a Pharma's Almanac Q1 issue

Due to its nature, the pharmaceutical industry will always see M&A activity. That is not likely to change anytime soon. However, the drivers behind it do change over time, based on the trends in the market.

Read more
C<sup>2</sup> PHARMA Expands Advisory Board to Support Growth Objectives

Press Release / 3. March 2020

C2 PHARMA Expands Advisory Board to Support Growth Objectives

Luxembourg, March 3, 2020 – C2 PHARMA (C2P), a Luxembourg-based phytochemical and chemical pharmaceutical manufacturing and distribution group, has expanded their advisory board with a new member. Consisting of well-respected pharmaceutical industry experts, the board provides strategic guidance on the progress and growth of the company via organic and M&A activities in the mid and long-term.

Read more
C<sup>2</sup> PHARMA highlights importance of API quality, an in-Pharma Technologist Featured Story

General / 19. February 2020

C2 PHARMA highlights importance of API quality, an in-Pharma Technologist Featured Story

The quality of active pharmaceutical ingredients (APIs) is a constant source of discussion within the industry. As C2 PHARMA works to expand its API portfolio, its CEO states that there is ‘no short game’ on API quality.

Read more
Fairness in the pharma supply chain key to success in today’s business climate, a Chemicals Knowledge featured story

General / 9. January 2020

Fairness in the pharma supply chain key to success in today’s business climate, a Chemicals Knowledge featured story

Andrew Badrot, CEO of C2 PHARMA, explains that times are changing for pharma, and considers some of the factors impacting the future of the industry as we enter 2020.

Read more
Andrew Badrot, CEO of C<sup>2</sup> PHARMA, speaks on developing technologies that will have the greatest impact on the biopharma industry in 2020 and beyond

General / 6. December 2019

Andrew Badrot, CEO of C2 PHARMA, speaks on developing technologies that will have the greatest impact on the biopharma industry in 2020 and beyond

C2 PHARMA in Pharma’s Almanac Q4 issue

Read more
Chemicals Knowledge features story on C<sup>2</sup> Pharma's portfolio expansion

General / 6. November 2019

Chemicals Knowledge features story on C2 Pharma's portfolio expansion

C2 PHARMA continues to build its active pharmaceutical ingredient (API) and botanical extracts product portfolio.

Read more
C<sup>2</sup> PHARMA Continues to Expand API Portfolio with Digoxin Micronized Grade, Homatropine Hydrobromide and Multiple Products Under Tech Transfer and Development

General / 4. November 2019

C2 PHARMA Continues to Expand API Portfolio with Digoxin Micronized Grade, Homatropine Hydrobromide and Multiple Products Under Tech Transfer and Development

Luxembourg, November 4, 2019 – C2 PHARMA (C2P), a Luxembourg-based phytochemical and chemical pharmaceutical manufacturing and distribution group, continues to build its active pharmaceutical ingredient (API) and botanical extracts product portfolio. The most recent addition enhances the previously announced Digoxin API product offer with the inclusion of a micronized grade for Digoxin from two different manufacturing sites. Multiple niche APIs and botanical extract products are also currently in technical transfer or under development, including Cannabidiol (CBD) and Tetrahydrocannabinol (THC).

Read more
C<sup>2</sup> PHARMA leverages virtual manufacturing to build secure supply chains, a Chemicals Knowledge featured story

General / 2. September 2019

C2 PHARMA leverages virtual manufacturing to build secure supply chains, a Chemicals Knowledge featured story

James Lawler, Head of Quality and External Supply Operations at C2 PHARMA, explains how the implementation of virtual manufacturing strategies can ensure supply chain security and the reliable delivery of high-quality active pharmaceutical ingredients (API).

Read more
Why the industry is forming bonds with CBD

General / 1. July 2019

Why the industry is forming bonds with CBD

C2 PHARMA in Pharma Manufacturing Featured story

Read more
Building resilient supply chains for niche APIs How C² PHARMA overcame the Digoxin challenge

General / 6. June 2019

Building resilient supply chains for niche APIs How C² PHARMA overcame the Digoxin challenge

Manufacturing Chemist cover story June 2019.

Read more
C<sup>2</sup> PHARMA  Acquires Digoxin API Portfolio from Nobilus Ent to Guarantee Long-Term Quality and Supply Chain Security

Press Release / 20. March 2019

C2 PHARMA Acquires Digoxin API Portfolio from Nobilus Ent to Guarantee Long-Term Quality and Supply Chain Security

Luxembourg, March 18, 2019 – C2 PHARMA, a Luxembourg-based phytochemical and chemical pharmaceutical manufacturing and distribution group, has acquired the Digoxin API product portfolio of Polish company, Nobilus Ent, self-developed and inherited from Roche/Galenus Mannheim. Through the agreement, C2 PHARMA is the product owner, and Nobilus is a manufacturing partner and releasing entity for the API. Parallel manufacturing to ensure redundancy is supported by long-term partner, Laurus Labs, an India-based API manufacturer with an impeccable track record.

Read more
FINANCIAL TIMES GLOBAL PHARMACEUTICAL AND BIOTECHNOLOGY CONFERENCE

General / 22. November 2018

FINANCIAL TIMES GLOBAL PHARMACEUTICAL AND BIOTECHNOLOGY CONFERENCE

05 – 06 November 2018 | London
Keynote Interview: Medicinal Cannabis: Perspectives on a Growing Market, Evolving Regulations and a Nascent Supply Chain Andrew Badrot, Founder and CEO, C2 PHARMA

Read more
C<sup>2</sup> PHARMA and ANKLAM EXTRAKT® announce R&D collaboration to develop cannabidiol-based compounds

Press Release / 5. October 2018

C2 PHARMA and ANKLAM EXTRAKT® announce R&D collaboration to develop cannabidiol-based compounds

Luxembourg and Anklam, October 5, 2018 – C2 PHARMA (Hall 6, Booth 6F40) and ANKLAM EXTRAKT (Hall 5, Booth 5G60) are announcing at CPhI 2018 in Madrid their R&D collaboration to develop GMP-compliant manufacture of cannabidiol CBD-based compounds. The collaboration between two leading companies in their respective fields covers various botanicals extracted from cannabis for pharmaceutical use.

Read more
C<sup>2</sup> PHARMA successfully completes validation campaigns for digoxin and digoxin micron

Press Release / 4. October 2018

C2 PHARMA successfully completes validation campaigns for digoxin and digoxin micron

Luxembourg, October 4, 2018 – C2 PHARMA (Hall 6, Booth 6F40) has successfully validated its manufacturing process for two APIs: digoxin and digoxin micron. Digoxin is produced at a dedicated manufacturing facility at CMO Laurus Labs, India.

Read more
C<sup>2</sup> PHARMA AND THERACULE ANNOUNCE STRATEGIC PARTNERSHIP

Press Release / 4. October 2018

C2 PHARMA AND THERACULE ANNOUNCE STRATEGIC PARTNERSHIP

Luxembourg and Oslo, October 4, 2018 – C2 PHARMA (Hall 6, Booth 6F40) and Theracule AS are entering into a strategic partnership focused on supporting Theracule’s new drug development programs aimed at rare neurodevelopmental disorders.

Read more
C<sup>2</sup> PHARMA brings reliable cannabidiol (cbd) api source to pharma companies and expands its r&d product pipeline

General / 2. October 2018

C2 PHARMA brings reliable cannabidiol (cbd) api source to pharma companies and expands its r&d product pipeline

Luxembourg, October 2, 2018 – C2 PHARMA (Hall 6, Booth 6F40) has announced a major expansion of its R&D program to grow its API portfolio at CPhI 2018 in Madrid. The R&D program covers synthetic APIs as well as naturally extracted APIs and botanicals for pharmaceutical use.

Read more
C<sup>2</sup> PHARMA buys out joint venture partner

Press Release / 22. June 2018

C2 PHARMA buys out joint venture partner

Luxembourg & São Paulo – 22 June, 2018 – C2 PHARMA has acquired the remaining 50 % of the shares in its joint venture from PAMA Holding, the investment vehicle of the Centroflora Group in Luxembourg. CEO Andrew Badrot is now the sole shareholder of C2 PHARMA.

Read more
CPhI 2017: C<sup>2</sup> PHARMA acquires R&D synthesis services company and establishes cold-chain logistics spin-off

General / 16. October 2017

CPhI 2017: C2 PHARMA acquires R&D synthesis services company and establishes cold-chain logistics spin-off

Luxembourg, October 16, 2017 – C2 PHARMA (Hall 11, Level 0, #B40), the company formerly known as Centroflora CMS, has announced the acquisition of German R&D synthesis services company ASM Research Chemicals in the run-up to the CPhI Worldwide exhibition in Frankfurt am Main, Germany on 24- 26 October 2017.

Read more
Centroflora CMS changes its name to C<sup>2</sup> PHARMA

General / 4. October 2017

Centroflora CMS changes its name to C2 PHARMA

Luxembourg, October 4, 2017 – Centroflora CMS, a Luxembourg-based venture between Swiss company CMS Pharma and Centroflora Group of Brazil, is changing its name to C2 PHARMA.

Read more
CPhI 2017: Centroflora CMS gains CEP approvals and invests in Digoxin manufacturing facility in India

General / 2. October 2017

CPhI 2017: Centroflora CMS gains CEP approvals and invests in Digoxin manufacturing facility in India

CEP approval for atropine sulfate; availability of US-DMFs for reference for both atropine sulfate and homatropine methylbromide.

Read more
CPhI 2017: Centroflora CMS nominated for the 2017 CPhI Pharma Award for Corporate Social Responsibility

General / 20. September 2017

CPhI 2017: Centroflora CMS nominated for the 2017 CPhI Pharma Award for Corporate Social Responsibility

Centroflora CMS has again been nominated for the CPhI Award in the category “Excellence in Pharma: Corporate Social Responsibility” for the project “Partnership for a Better World”. This is the second year in succession that the company has been in the running for the Award.

Read more
Centroflora CMS at CPhI 2017 in Frankfurt – booth 11.0.B40

General / 5. September 2017

Centroflora CMS at CPhI 2017 in Frankfurt – booth 11.0.B40

Please join us at our booth 11.0.B40 under the Brazilian Pavillion at CPhI Frankfurt on October 24 and 26, 2017.

Read more
Centroflora CMS is Selected as Finalist for the CPhI Pharma Awards 2016

General / 19. September 2016

Centroflora CMS is Selected as Finalist for the CPhI Pharma Awards 2016

Centroflora CMS is selected as a finalist for the CPhI Pharma Awards 2016 in the category Excellence in Pharma: Corporate Social Responsibility.

Read more
Centroflora CMS at CPhI 2016 in Barcelona – booth 3H10

General / 9. September 2016

Centroflora CMS at CPhI 2016 in Barcelona – booth 3H10

Please join us at our booth 3H10 under the Brazilian Pavillion at CPhI Barcelona on October 4 and 6, 2016.

Read more
Centroflora CMS is the winner of the 2015 CPhI Pharma Award for Excellence in Partnering & Outsourcing

General / 27. October 2015

Centroflora CMS is the winner of the 2015 CPhI Pharma Award for Excellence in Partnering & Outsourcing

We are pleased to announce that Centroflora CMS won the prestigious 2015 CPhI Pharma Awards for Excellence in Partnering & Outsourcing. Awarded by CPhI Worldwide (UBM EMEA), 16 finalists were invited to present their case during the first day of CPhI Worldwide in Madrid on October 13, 2015.

Read more
Centroflora CMS Expands its Product and Service Offering

General / 4. October 2015

Centroflora CMS Expands its Product and Service Offering

New service offering includes R&D leveraging a unique bioprospecting platform from the Brazilian biomes as well as contract manufacturing (CMO) services for both API and botanical extracts in Brazil.

Read more
Centroflora CMS is Selected as Finalist for the CPhI Pharma Awards 2015

General / 21. September 2015

Centroflora CMS is Selected as Finalist for the CPhI Pharma Awards 2015

Centroflora CMS is selected as a finalist for the CPhI Pharma Awards 2015.

Read more
Centroflora CMS at CPhI 2015 in Madrid

General / 1. September 2015

Centroflora CMS at CPhI 2015 in Madrid

Please join us at our booth 8D20 under the Brazilian Pavillion at CPhI Madrid between October 13 and 15, 2015.

Read more
Centroflora Group is Awarded 1st National Biodiversity Award

General / 22. May 2015

Centroflora Group is Awarded 1st National Biodiversity Award

Centroflora Group receives the Brazilian Ministry of Environment 1st National Biodiversity Award in recognition of the Jaborandi Valorization Project.

Read more
Firms Team Up To Sustain Natural Pilocarpine

General / 16. March 2015

Firms Team Up To Sustain Natural Pilocarpine

C&EN’s Rick Mullin writes about Centroflora CMS and Centroflora’s Partnership for a Better World.

Read more
Centroflora CMS at CPhI 2014 in Paris

General / 1. September 2014

Centroflora CMS at CPhI 2014 in Paris

Please join us at our booth 5P73 under the Brazilian Pavillion at CPhI Paris between October 7 and 9, 2014.

Read more